Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 11/20 | 0.69 |
| ▸ | CDK2 | P24941 | 9/20 | 0.69 |
| ▸ | CDK9 | P50750 | 9/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.69 |
| ▸ | CDK4 | P11802 | 3/20 | 0.69 |
| ▸ | CDK7 | P50613 | 3/20 | 0.69 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.69 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.66 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.66 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.66 |
| ▸ | CCNH | P51946 | 2/20 | 0.66 |
| ▸ | CCNT2 | O60583 | 2/20 | 0.66 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.66 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.66 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.66 |
| ▸ | CASK | O14936 | 1/20 | 0.66 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.66 |
| ▸ | GSK3A | P49840 | 1/20 | 0.66 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23683276 | 0.87 | CDK2 (0.69) | CDK1CDK2CDK9CDK5CDK4 | |
| SCHEMBL29100402 | 0.83 | CDK1 (0.49) | CDK1CDK2CDK9CDK5CDK4 | |
| SCHEMBL22355616 | 0.83 | CDK2 (0.78) | CDK1CDK2CDK9CDK5CDK4 | |
| SCHEMBL3302791 | 0.82 | CDK2 (0.63) | CDK1CDK2CDK9CDK5CDK5R1 | |
| SCHEMBL3300764 | 0.81 | CDK2 (0.65) | CDK1CDK2CDK9CDK5CDK4 | |
| SCHEMBL24669099 | 0.80 | CDK2 (0.83) | CDK1CDK2CDK9CDK5CDK4 | |
| SCHEMBL23683383 | 0.80 | CDK2 (0.77) | CDK1CDK2CDK9CDK5CDK4 | |
| Cyc-065 SCHEMBL13300946 | 0.80 | CDK2 (1.00) | CDK1CDK2CDK9CDK5CDK4 | |
| SCHEMBL23683392 | 0.80 | CDK2 (0.77) | CDK1CDK2CDK9CDK5CDK4 | |
| Cyc-065 SCHEMBL31702790 | 0.80 | CDK2 (1.00) | CDK1CDK2CDK9CDK5CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813621-A | 9H purine compounds, pharmaceutical composition and application thereof | 江南大学 | 2023-09-29 | — | — | CN | disclosed |
| EP-4212533-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | Cyclacel Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-20230104823-A1 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | CYCLACEL LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-3573988-B1 | PROCESS FOR PREPARING PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-10927113-B2 | Process for preparing purine derivatives | CYCLACEL LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| CN-107400134-B | Crystalline forms of purine derivatives | 西克拉塞尔有限公司 | 2020-09-29 | — | — | CN | disclosed |
| WO-2018138500-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| EP-3150602-B1 | CRYSTALLINE FORMS OF A PURINE DERIVATIVE | CYCLACEL LTD (GB) | 2018-08-01 | — | — | EP | disclosed |
| EP-3150602-A1 | CRYSTALLINE FORMS OF A PURINE DERIVATIVE | Cyclacel Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093769-A1 | COMPOUNDS | CYCLACEL LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| CN-101679434-A | Has 2,6 of anti proliferative properties, the purine derivative that 9-replaces | CYCLACEL LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2139893-A2 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTIPROLIFERATIVE PROPERTIES | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| EP-2139486-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122767-A2 | 2, 6, 9-SUBSTITUTED PURINE DERIVATIVES HAVING ANTI PROLIFERATIVE PROPERTIES | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122779-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122779-A1 | COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093769-A1 | COMPOUNDS | CCR9, NPY1R, BCL9 | CDK1 512/4885CDK2 1751/4885CDK9 57/4885 |
| US-10927113-B2 | Process for preparing purine derivatives | CTR9, PNP, C5 | CDK1 2024/4885CDK2 2940/4885CDK9 476/4885 |
| US-20230104823-A1 | PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY | CDK9, CDK19, CDK7 | CDK1 5/4885CDK2 10/4885CDK9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.